Continuing Education (CME)
“Pediatric SNO-Storm: A Collaborative Brainstorm Addressing Challenging Pediatric CNS Tumors from Around the World”
Infant High-Grade Glioma: Not All High-Grade Gliomas Are Born Equal
Enduring CME Activity
Activity Launch Date: August 18, 2025
Activity Expiration Date: August 18, 2027
Deadline to Claim Credit: August 18, 2027, at 11:59 pm ET
This activity is provided by the Society for Neuro-Oncology.
Please note, if you participated in the live activity, you are not eligible to claim credit for the enduring activity.
Target Audience
Oncologists, Neuro-Oncologists, Pediatric Oncologists, Neurosurgeons, Radiation Oncologists, Neurologists, Pathologists, Oncology and Neuro-oncology trainees, Oncology nurses and Nurse Practitioners. There is a pediatric focus to the presented material.
Statement of Need/Program Overview
Infant-type hemispheric glioma is a new category of pediatric high-grade glioma (HGG) as of the 2021 update to the WHO classification of CNS tumors. These tumors are biologically distinct from HGG in older children in terms of molecular drivers, and they also have more favorable outcomes in many cases. However, management of these tumors in infants presents unique challenges as well. In this webinar, we intend to review and discuss current understanding of the molecular characteristics, subgrouping, treatment challenges, and therapeutic approaches to infant HGG.
Educational Objectives
After participating in this CME activity, participants should be able to:
- Identify biological features and groups of infant HGG that distinguish them from HGG in older children and adults
- Discuss unique challenges in the treatment of infant HGG
- Discuss initial treatment approaches to infant HGG and the data supporting them
Program Agenda
Agenda
Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
The Society for Neuro-Oncology designates the enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit, Claim Certificate of Participation
- Register for the enduring activity through the Neuro-Oncology Academy.
- View the entire recording.
- Complete the evaluation and application for credit.
- Download the CME certificate or certificate of participation from "My Learning Dashboard" located on the left-hand side menu bar.
- Cerficiates of credit should be claimed by physicians (MD, DO, MD/PhD).
- Certificates of participation should be claimed by non-physicians.
Activity Expiration Date: August 18, 2027
Deadline to Claim Credit: August 18, 2027, at 11:59 pm ET
Disclosure of Relevant Financial RelationshipsThe Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view the list of disclosures,
click here.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Buchanan, RN at
melesa@soc-neuro-onc.org
For techical assistance with claiming CME credit or certificate of participation, please email
academy@soc-neuro-onc.org.
